ArticleOncotarget2017

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.

Anne-Christine Wong Te Fong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.